nodes	percent_of_prediction	percent_of_DWPC	metapath
Norfloxacin—TOP2A—Mitoxantrone—multiple sclerosis	0.254	0.339	CbGbCtD
Norfloxacin—CYP2A6—Prednisolone—multiple sclerosis	0.0893	0.12	CbGbCtD
Norfloxacin—CYP2A6—Dexamethasone—multiple sclerosis	0.0527	0.0705	CbGbCtD
Norfloxacin—CYP1A1—Dexamethasone—multiple sclerosis	0.045	0.0602	CbGbCtD
Norfloxacin—CYP3A4—Fingolimod—multiple sclerosis	0.0432	0.0578	CbGbCtD
Norfloxacin—CYP3A7-CYP3A51P—Dexamethasone—multiple sclerosis	0.036	0.0482	CbGbCtD
Norfloxacin—CYP3A7—Dexamethasone—multiple sclerosis	0.036	0.0482	CbGbCtD
Norfloxacin—SLC22A6—Methotrexate—multiple sclerosis	0.0317	0.0424	CbGbCtD
Norfloxacin—CYP3A4—Methylprednisolone—multiple sclerosis	0.0278	0.0373	CbGbCtD
Norfloxacin—CYP3A5—Dexamethasone—multiple sclerosis	0.027	0.0362	CbGbCtD
Norfloxacin—CYP3A4—Triamcinolone—multiple sclerosis	0.0211	0.0282	CbGbCtD
Norfloxacin—CYP3A4—Mitoxantrone—multiple sclerosis	0.0203	0.0272	CbGbCtD
Norfloxacin—CYP3A4—Betamethasone—multiple sclerosis	0.0181	0.0242	CbGbCtD
Norfloxacin—CYP3A4—Prednisolone—multiple sclerosis	0.0179	0.0239	CbGbCtD
Norfloxacin—CYP3A4—Prednisone—multiple sclerosis	0.0169	0.0226	CbGbCtD
Norfloxacin—CYP3A4—Dexamethasone—multiple sclerosis	0.0105	0.0141	CbGbCtD
Norfloxacin—TOP2A—Floxuridine—Cladribine—multiple sclerosis	0.00157	0.378	CbGdCrCtD
Norfloxacin—TOP2A—Clofarabine—Cladribine—multiple sclerosis	0.0011	0.265	CbGdCrCtD
Norfloxacin—TOP2A—Azacitidine—Cladribine—multiple sclerosis	0.000668	0.161	CbGdCrCtD
Norfloxacin—CYP2A6—Fluoropyrimidine Activity—RRM1—multiple sclerosis	0.000417	0.0207	CbGpPWpGaD
Norfloxacin—TOP2A—Methyltestosterone—Prednisone—multiple sclerosis	0.000409	0.0989	CbGdCrCtD
Norfloxacin—TOP2A—Methyltestosterone—Prednisolone—multiple sclerosis	0.0004	0.0966	CbGdCrCtD
Norfloxacin—CYP3A5—Irinotecan Pathway—BCHE—multiple sclerosis	0.000375	0.0186	CbGpPWpGaD
Norfloxacin—CYP3A7—Cytochrome P450 - arranged by substrate type—CYP24A1—multiple sclerosis	0.000372	0.0185	CbGpPWpGaD
Norfloxacin—CYP3A7—Cytochrome P450 - arranged by substrate type—CYP27B1—multiple sclerosis	0.000372	0.0185	CbGpPWpGaD
Norfloxacin—CYP3A7—Oxidation by Cytochrome P450—CYP27B1—multiple sclerosis	0.000367	0.0182	CbGpPWpGaD
Norfloxacin—CYP3A7—Oxidation by Cytochrome P450—CYP24A1—multiple sclerosis	0.000367	0.0182	CbGpPWpGaD
Norfloxacin—TOP2A—Retinoblastoma (RB) in Cancer—RRM1—multiple sclerosis	0.000347	0.0172	CbGpPWpGaD
Norfloxacin—CYP2A6—Cytochrome P450 - arranged by substrate type—CYP24A1—multiple sclerosis	0.000341	0.0169	CbGpPWpGaD
Norfloxacin—CYP2A6—Cytochrome P450 - arranged by substrate type—CYP27B1—multiple sclerosis	0.000341	0.0169	CbGpPWpGaD
Norfloxacin—CYP2A6—Oxidation by Cytochrome P450—CYP27B1—multiple sclerosis	0.000336	0.0167	CbGpPWpGaD
Norfloxacin—CYP2A6—Oxidation by Cytochrome P450—CYP24A1—multiple sclerosis	0.000336	0.0167	CbGpPWpGaD
Norfloxacin—SLC22A5—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC30A7—multiple sclerosis	0.000327	0.0163	CbGpPWpGaD
Norfloxacin—CYP3A7—Phase 1 - Functionalization of compounds—CYP27B1—multiple sclerosis	0.000301	0.015	CbGpPWpGaD
Norfloxacin—CYP3A7—Phase 1 - Functionalization of compounds—CYP24A1—multiple sclerosis	0.000301	0.015	CbGpPWpGaD
Norfloxacin—Nausea—Cladribine—multiple sclerosis	0.000288	0.00126	CcSEcCtD
Norfloxacin—Vertigo—Prednisolone—multiple sclerosis	0.000288	0.00126	CcSEcCtD
Norfloxacin—Paraesthesia—Mitoxantrone—multiple sclerosis	0.000286	0.00125	CcSEcCtD
Norfloxacin—Back pain—Triamcinolone—multiple sclerosis	0.000285	0.00125	CcSEcCtD
Norfloxacin—Dyspnoea—Mitoxantrone—multiple sclerosis	0.000284	0.00124	CcSEcCtD
Norfloxacin—Somnolence—Mitoxantrone—multiple sclerosis	0.000283	0.00124	CcSEcCtD
Norfloxacin—Dyspepsia—Mitoxantrone—multiple sclerosis	0.00028	0.00123	CcSEcCtD
Norfloxacin—Convulsion—Prednisolone—multiple sclerosis	0.000277	0.00121	CcSEcCtD
Norfloxacin—Decreased appetite—Mitoxantrone—multiple sclerosis	0.000277	0.00121	CcSEcCtD
Norfloxacin—Eosinophilia—Methotrexate—multiple sclerosis	0.000276	0.00121	CcSEcCtD
Norfloxacin—CYP2A6—Phase 1 - Functionalization of compounds—CYP24A1—multiple sclerosis	0.000276	0.0137	CbGpPWpGaD
Norfloxacin—CYP2A6—Phase 1 - Functionalization of compounds—CYP27B1—multiple sclerosis	0.000276	0.0137	CbGpPWpGaD
Norfloxacin—Fatigue—Mitoxantrone—multiple sclerosis	0.000275	0.0012	CcSEcCtD
Norfloxacin—Pancreatitis—Methotrexate—multiple sclerosis	0.000274	0.0012	CcSEcCtD
Norfloxacin—Constipation—Mitoxantrone—multiple sclerosis	0.000272	0.00119	CcSEcCtD
Norfloxacin—Diarrhoea—Azathioprine—multiple sclerosis	0.00027	0.00118	CcSEcCtD
Norfloxacin—Angioedema—Triamcinolone—multiple sclerosis	0.000269	0.00118	CcSEcCtD
Norfloxacin—CYP3A5—Cytochrome P450 - arranged by substrate type—CYP24A1—multiple sclerosis	0.000269	0.0134	CbGpPWpGaD
Norfloxacin—CYP3A5—Cytochrome P450 - arranged by substrate type—CYP27B1—multiple sclerosis	0.000269	0.0134	CbGpPWpGaD
Norfloxacin—Angioedema—Methylprednisolone—multiple sclerosis	0.000269	0.00117	CcSEcCtD
Norfloxacin—Erythema—Dexamethasone—multiple sclerosis	0.000267	0.00117	CcSEcCtD
Norfloxacin—Erythema—Betamethasone—multiple sclerosis	0.000267	0.00117	CcSEcCtD
Norfloxacin—Hallucination—Prednisone—multiple sclerosis	0.000266	0.00116	CcSEcCtD
Norfloxacin—CYP3A5—Oxidation by Cytochrome P450—CYP27B1—multiple sclerosis	0.000265	0.0132	CbGpPWpGaD
Norfloxacin—CYP3A5—Oxidation by Cytochrome P450—CYP24A1—multiple sclerosis	0.000265	0.0132	CbGpPWpGaD
Norfloxacin—Vertigo—Triamcinolone—multiple sclerosis	0.000265	0.00116	CcSEcCtD
Norfloxacin—Vertigo—Methylprednisolone—multiple sclerosis	0.000264	0.00115	CcSEcCtD
Norfloxacin—Feeling abnormal—Mitoxantrone—multiple sclerosis	0.000263	0.00115	CcSEcCtD
Norfloxacin—Oedema—Prednisolone—multiple sclerosis	0.000261	0.00114	CcSEcCtD
Norfloxacin—Anaphylactic shock—Prednisolone—multiple sclerosis	0.000261	0.00114	CcSEcCtD
Norfloxacin—Neutropenia—Methotrexate—multiple sclerosis	0.000261	0.00114	CcSEcCtD
Norfloxacin—Dizziness—Azathioprine—multiple sclerosis	0.000261	0.00114	CcSEcCtD
Norfloxacin—Gastrointestinal pain—Mitoxantrone—multiple sclerosis	0.000261	0.00114	CcSEcCtD
Norfloxacin—Convulsion—Triamcinolone—multiple sclerosis	0.000255	0.00112	CcSEcCtD
Norfloxacin—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP27B1—multiple sclerosis	0.000255	0.0127	CbGpPWpGaD
Norfloxacin—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP24A1—multiple sclerosis	0.000255	0.0127	CbGpPWpGaD
Norfloxacin—Photosensitivity reaction—Methotrexate—multiple sclerosis	0.000255	0.00111	CcSEcCtD
Norfloxacin—Convulsion—Methylprednisolone—multiple sclerosis	0.000255	0.00111	CcSEcCtD
Norfloxacin—CYP1A1—Cytochrome P450 - arranged by substrate type—CYP27B1—multiple sclerosis	0.000254	0.0126	CbGpPWpGaD
Norfloxacin—CYP1A1—Cytochrome P450 - arranged by substrate type—CYP24A1—multiple sclerosis	0.000254	0.0126	CbGpPWpGaD
Norfloxacin—Urticaria—Mitoxantrone—multiple sclerosis	0.000253	0.00111	CcSEcCtD
Norfloxacin—Hyperhidrosis—Prednisolone—multiple sclerosis	0.000253	0.00111	CcSEcCtD
Norfloxacin—Body temperature increased—Mitoxantrone—multiple sclerosis	0.000252	0.0011	CcSEcCtD
Norfloxacin—Abdominal pain—Mitoxantrone—multiple sclerosis	0.000252	0.0011	CcSEcCtD
Norfloxacin—Myalgia—Triamcinolone—multiple sclerosis	0.000251	0.0011	CcSEcCtD
Norfloxacin—Vomiting—Azathioprine—multiple sclerosis	0.000251	0.0011	CcSEcCtD
Norfloxacin—CYP1A1—Oxidation by Cytochrome P450—CYP24A1—multiple sclerosis	0.000251	0.0124	CbGpPWpGaD
Norfloxacin—CYP1A1—Oxidation by Cytochrome P450—CYP27B1—multiple sclerosis	0.000251	0.0124	CbGpPWpGaD
Norfloxacin—Myalgia—Methylprednisolone—multiple sclerosis	0.00025	0.00109	CcSEcCtD
Norfloxacin—Arthralgia—Methylprednisolone—multiple sclerosis	0.00025	0.00109	CcSEcCtD
Norfloxacin—Anxiety—Methylprednisolone—multiple sclerosis	0.000249	0.00109	CcSEcCtD
Norfloxacin—Drowsiness—Methotrexate—multiple sclerosis	0.000249	0.00109	CcSEcCtD
Norfloxacin—Rash—Azathioprine—multiple sclerosis	0.000248	0.00109	CcSEcCtD
Norfloxacin—Dermatitis—Azathioprine—multiple sclerosis	0.000248	0.00109	CcSEcCtD
Norfloxacin—SLC22A6—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC30A7—multiple sclerosis	0.000247	0.0123	CbGpPWpGaD
Norfloxacin—Headache—Azathioprine—multiple sclerosis	0.000247	0.00108	CcSEcCtD
Norfloxacin—Stevens-Johnson syndrome—Methotrexate—multiple sclerosis	0.000247	0.00108	CcSEcCtD
Norfloxacin—Dry mouth—Triamcinolone—multiple sclerosis	0.000245	0.00107	CcSEcCtD
Norfloxacin—TOP2A—Validated transcriptional targets of deltaNp63 isoforms—VDR—multiple sclerosis	0.000245	0.0122	CbGpPWpGaD
Norfloxacin—Renal failure—Methotrexate—multiple sclerosis	0.000245	0.00107	CcSEcCtD
Norfloxacin—Angioedema—Dexamethasone—multiple sclerosis	0.000244	0.00107	CcSEcCtD
Norfloxacin—Angioedema—Betamethasone—multiple sclerosis	0.000244	0.00107	CcSEcCtD
Norfloxacin—Stomatitis—Methotrexate—multiple sclerosis	0.000243	0.00106	CcSEcCtD
Norfloxacin—Conjunctivitis—Methotrexate—multiple sclerosis	0.000242	0.00106	CcSEcCtD
Norfloxacin—Confusional state—Methylprednisolone—multiple sclerosis	0.000242	0.00106	CcSEcCtD
Norfloxacin—Anaphylactic shock—Triamcinolone—multiple sclerosis	0.00024	0.00105	CcSEcCtD
Norfloxacin—Oedema—Triamcinolone—multiple sclerosis	0.00024	0.00105	CcSEcCtD
Norfloxacin—Vertigo—Betamethasone—multiple sclerosis	0.00024	0.00105	CcSEcCtD
Norfloxacin—Vertigo—Dexamethasone—multiple sclerosis	0.00024	0.00105	CcSEcCtD
Norfloxacin—Anaphylactic shock—Methylprednisolone—multiple sclerosis	0.00024	0.00105	CcSEcCtD
Norfloxacin—Haematuria—Methotrexate—multiple sclerosis	0.000237	0.00104	CcSEcCtD
Norfloxacin—Insomnia—Prednisolone—multiple sclerosis	0.000236	0.00103	CcSEcCtD
Norfloxacin—Hypersensitivity—Mitoxantrone—multiple sclerosis	0.000235	0.00103	CcSEcCtD
Norfloxacin—Paraesthesia—Prednisolone—multiple sclerosis	0.000235	0.00103	CcSEcCtD
Norfloxacin—Nausea—Azathioprine—multiple sclerosis	0.000234	0.00102	CcSEcCtD
Norfloxacin—Erythema—Prednisone—multiple sclerosis	0.000233	0.00102	CcSEcCtD
Norfloxacin—Hyperhidrosis—Triamcinolone—multiple sclerosis	0.000232	0.00102	CcSEcCtD
Norfloxacin—Agranulocytosis—Methotrexate—multiple sclerosis	0.000232	0.00102	CcSEcCtD
Norfloxacin—Hyperhidrosis—Methylprednisolone—multiple sclerosis	0.000232	0.00101	CcSEcCtD
Norfloxacin—Convulsion—Dexamethasone—multiple sclerosis	0.000232	0.00101	CcSEcCtD
Norfloxacin—Convulsion—Betamethasone—multiple sclerosis	0.000232	0.00101	CcSEcCtD
Norfloxacin—SLC22A5—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC11A1—multiple sclerosis	0.000229	0.0114	CbGpPWpGaD
Norfloxacin—Asthenia—Mitoxantrone—multiple sclerosis	0.000229	0.001	CcSEcCtD
Norfloxacin—Myalgia—Dexamethasone—multiple sclerosis	0.000228	0.000995	CcSEcCtD
Norfloxacin—Myalgia—Betamethasone—multiple sclerosis	0.000228	0.000995	CcSEcCtD
Norfloxacin—Anxiety—Dexamethasone—multiple sclerosis	0.000227	0.000992	CcSEcCtD
Norfloxacin—Anxiety—Betamethasone—multiple sclerosis	0.000227	0.000992	CcSEcCtD
Norfloxacin—Hepatitis—Methotrexate—multiple sclerosis	0.000223	0.000977	CcSEcCtD
Norfloxacin—Vision blurred—Prednisone—multiple sclerosis	0.000219	0.000959	CcSEcCtD
Norfloxacin—Musculoskeletal discomfort—Triamcinolone—multiple sclerosis	0.000219	0.000958	CcSEcCtD
Norfloxacin—Musculoskeletal discomfort—Methylprednisolone—multiple sclerosis	0.000219	0.000956	CcSEcCtD
Norfloxacin—Anaphylactic shock—Dexamethasone—multiple sclerosis	0.000218	0.000954	CcSEcCtD
Norfloxacin—Oedema—Betamethasone—multiple sclerosis	0.000218	0.000954	CcSEcCtD
Norfloxacin—Anaphylactic shock—Betamethasone—multiple sclerosis	0.000218	0.000954	CcSEcCtD
Norfloxacin—Oedema—Dexamethasone—multiple sclerosis	0.000218	0.000954	CcSEcCtD
Norfloxacin—Diarrhoea—Mitoxantrone—multiple sclerosis	0.000218	0.000954	CcSEcCtD
Norfloxacin—CYP3A5—Phase 1 - Functionalization of compounds—CYP24A1—multiple sclerosis	0.000218	0.0108	CbGpPWpGaD
Norfloxacin—CYP3A5—Phase 1 - Functionalization of compounds—CYP27B1—multiple sclerosis	0.000218	0.0108	CbGpPWpGaD
Norfloxacin—CYP1A1—Aryl Hydrocarbon Receptor Pathway—IL12A—multiple sclerosis	0.000218	0.0108	CbGpPWpGaD
Norfloxacin—Insomnia—Triamcinolone—multiple sclerosis	0.000217	0.000951	CcSEcCtD
Norfloxacin—Insomnia—Methylprednisolone—multiple sclerosis	0.000217	0.000949	CcSEcCtD
Norfloxacin—Paraesthesia—Triamcinolone—multiple sclerosis	0.000216	0.000944	CcSEcCtD
Norfloxacin—Feeling abnormal—Prednisolone—multiple sclerosis	0.000215	0.000942	CcSEcCtD
Norfloxacin—Paraesthesia—Methylprednisolone—multiple sclerosis	0.000215	0.000942	CcSEcCtD
Norfloxacin—Visual impairment—Methotrexate—multiple sclerosis	0.000215	0.000942	CcSEcCtD
Norfloxacin—Dyspnoea—Triamcinolone—multiple sclerosis	0.000214	0.000937	CcSEcCtD
Norfloxacin—Agitation—Prednisone—multiple sclerosis	0.000214	0.000936	CcSEcCtD
Norfloxacin—Thrombocytopenia—Dexamethasone—multiple sclerosis	0.000214	0.000934	CcSEcCtD
Norfloxacin—Thrombocytopenia—Betamethasone—multiple sclerosis	0.000214	0.000934	CcSEcCtD
Norfloxacin—Angioedema—Prednisone—multiple sclerosis	0.000213	0.00093	CcSEcCtD
Norfloxacin—Dyspepsia—Triamcinolone—multiple sclerosis	0.000212	0.000926	CcSEcCtD
Norfloxacin—Erythema multiforme—Methotrexate—multiple sclerosis	0.000211	0.000924	CcSEcCtD
Norfloxacin—Dyspepsia—Methylprednisolone—multiple sclerosis	0.000211	0.000923	CcSEcCtD
Norfloxacin—Hyperhidrosis—Betamethasone—multiple sclerosis	0.000211	0.000922	CcSEcCtD
Norfloxacin—Hyperhidrosis—Dexamethasone—multiple sclerosis	0.000211	0.000922	CcSEcCtD
Norfloxacin—Vertigo—Prednisone—multiple sclerosis	0.000209	0.000915	CcSEcCtD
Norfloxacin—Tinnitus—Methotrexate—multiple sclerosis	0.000208	0.000911	CcSEcCtD
Norfloxacin—Anorexia—Betamethasone—multiple sclerosis	0.000208	0.000909	CcSEcCtD
Norfloxacin—Anorexia—Dexamethasone—multiple sclerosis	0.000208	0.000909	CcSEcCtD
Norfloxacin—Urticaria—Prednisolone—multiple sclerosis	0.000208	0.000908	CcSEcCtD
Norfloxacin—Fatigue—Triamcinolone—multiple sclerosis	0.000207	0.000906	CcSEcCtD
Norfloxacin—Fatigue—Methylprednisolone—multiple sclerosis	0.000207	0.000904	CcSEcCtD
Norfloxacin—CYP1A1—Phase 1 - Functionalization of compounds—CYP24A1—multiple sclerosis	0.000206	0.0102	CbGpPWpGaD
Norfloxacin—CYP1A1—Phase 1 - Functionalization of compounds—CYP27B1—multiple sclerosis	0.000206	0.0102	CbGpPWpGaD
Norfloxacin—Vomiting—Mitoxantrone—multiple sclerosis	0.000203	0.000886	CcSEcCtD
Norfloxacin—Convulsion—Prednisone—multiple sclerosis	0.000202	0.000882	CcSEcCtD
Norfloxacin—Rash—Mitoxantrone—multiple sclerosis	0.000201	0.000879	CcSEcCtD
Norfloxacin—Dermatitis—Mitoxantrone—multiple sclerosis	0.000201	0.000878	CcSEcCtD
Norfloxacin—Chills—Methotrexate—multiple sclerosis	0.0002	0.000877	CcSEcCtD
Norfloxacin—Headache—Mitoxantrone—multiple sclerosis	0.0002	0.000873	CcSEcCtD
Norfloxacin—Musculoskeletal discomfort—Betamethasone—multiple sclerosis	0.000199	0.000869	CcSEcCtD
Norfloxacin—Musculoskeletal discomfort—Dexamethasone—multiple sclerosis	0.000199	0.000869	CcSEcCtD
Norfloxacin—Arthralgia—Prednisone—multiple sclerosis	0.000198	0.000867	CcSEcCtD
Norfloxacin—Myalgia—Prednisone—multiple sclerosis	0.000198	0.000867	CcSEcCtD
Norfloxacin—Feeling abnormal—Triamcinolone—multiple sclerosis	0.000198	0.000866	CcSEcCtD
Norfloxacin—Feeling abnormal—Methylprednisolone—multiple sclerosis	0.000198	0.000865	CcSEcCtD
Norfloxacin—Anxiety—Prednisone—multiple sclerosis	0.000197	0.000864	CcSEcCtD
Norfloxacin—Insomnia—Dexamethasone—multiple sclerosis	0.000197	0.000863	CcSEcCtD
Norfloxacin—Insomnia—Betamethasone—multiple sclerosis	0.000197	0.000863	CcSEcCtD
Norfloxacin—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP24A1—multiple sclerosis	0.000197	0.00978	CbGpPWpGaD
Norfloxacin—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP27B1—multiple sclerosis	0.000197	0.00978	CbGpPWpGaD
Norfloxacin—SLC22A5—SLC-mediated transmembrane transport—SLC15A2—multiple sclerosis	0.000196	0.00975	CbGpPWpGaD
Norfloxacin—Gastrointestinal pain—Methylprednisolone—multiple sclerosis	0.000196	0.000858	CcSEcCtD
Norfloxacin—Paraesthesia—Betamethasone—multiple sclerosis	0.000196	0.000857	CcSEcCtD
Norfloxacin—Paraesthesia—Dexamethasone—multiple sclerosis	0.000196	0.000857	CcSEcCtD
Norfloxacin—Erythema—Methotrexate—multiple sclerosis	0.000195	0.000851	CcSEcCtD
Norfloxacin—Hypersensitivity—Prednisolone—multiple sclerosis	0.000193	0.000842	CcSEcCtD
Norfloxacin—Dyspepsia—Betamethasone—multiple sclerosis	0.000192	0.00084	CcSEcCtD
Norfloxacin—Dyspepsia—Dexamethasone—multiple sclerosis	0.000192	0.00084	CcSEcCtD
Norfloxacin—Urticaria—Triamcinolone—multiple sclerosis	0.000191	0.000835	CcSEcCtD
Norfloxacin—Urticaria—Methylprednisolone—multiple sclerosis	0.000191	0.000833	CcSEcCtD
Norfloxacin—Dysgeusia—Methotrexate—multiple sclerosis	0.00019	0.000833	CcSEcCtD
Norfloxacin—Body temperature increased—Triamcinolone—multiple sclerosis	0.00019	0.000831	CcSEcCtD
Norfloxacin—Anaphylactic shock—Prednisone—multiple sclerosis	0.00019	0.000831	CcSEcCtD
Norfloxacin—Oedema—Prednisone—multiple sclerosis	0.00019	0.000831	CcSEcCtD
Norfloxacin—Abdominal pain—Methylprednisolone—multiple sclerosis	0.00019	0.000829	CcSEcCtD
Norfloxacin—Decreased appetite—Betamethasone—multiple sclerosis	0.00019	0.000829	CcSEcCtD
Norfloxacin—Decreased appetite—Dexamethasone—multiple sclerosis	0.00019	0.000829	CcSEcCtD
Norfloxacin—Nausea—Mitoxantrone—multiple sclerosis	0.000189	0.000828	CcSEcCtD
Norfloxacin—Back pain—Methotrexate—multiple sclerosis	0.000188	0.000823	CcSEcCtD
Norfloxacin—Fatigue—Betamethasone—multiple sclerosis	0.000188	0.000823	CcSEcCtD
Norfloxacin—Fatigue—Dexamethasone—multiple sclerosis	0.000188	0.000823	CcSEcCtD
Norfloxacin—TOP2A—Integrated Pancreatic Cancer Pathway—RRM1—multiple sclerosis	0.000185	0.00918	CbGpPWpGaD
Norfloxacin—Hyperhidrosis—Prednisone—multiple sclerosis	0.000184	0.000803	CcSEcCtD
Norfloxacin—Vision blurred—Methotrexate—multiple sclerosis	0.000183	0.000802	CcSEcCtD
Norfloxacin—Anorexia—Prednisone—multiple sclerosis	0.000181	0.000792	CcSEcCtD
Norfloxacin—Feeling abnormal—Dexamethasone—multiple sclerosis	0.00018	0.000786	CcSEcCtD
Norfloxacin—Feeling abnormal—Betamethasone—multiple sclerosis	0.00018	0.000786	CcSEcCtD
Norfloxacin—Gastrointestinal pain—Betamethasone—multiple sclerosis	0.000178	0.00078	CcSEcCtD
Norfloxacin—Gastrointestinal pain—Dexamethasone—multiple sclerosis	0.000178	0.00078	CcSEcCtD
Norfloxacin—Hypersensitivity—Triamcinolone—multiple sclerosis	0.000177	0.000775	CcSEcCtD
Norfloxacin—Hypersensitivity—Methylprednisolone—multiple sclerosis	0.000177	0.000773	CcSEcCtD
Norfloxacin—Vertigo—Methotrexate—multiple sclerosis	0.000175	0.000764	CcSEcCtD
Norfloxacin—CYP3A4—Irinotecan Pathway—BCHE—multiple sclerosis	0.000174	0.00866	CbGpPWpGaD
Norfloxacin—Leukopenia—Methotrexate—multiple sclerosis	0.000174	0.000762	CcSEcCtD
Norfloxacin—Urticaria—Dexamethasone—multiple sclerosis	0.000173	0.000758	CcSEcCtD
Norfloxacin—Urticaria—Betamethasone—multiple sclerosis	0.000173	0.000758	CcSEcCtD
Norfloxacin—Musculoskeletal discomfort—Prednisone—multiple sclerosis	0.000173	0.000757	CcSEcCtD
Norfloxacin—Dizziness—Prednisolone—multiple sclerosis	0.000173	0.000756	CcSEcCtD
Norfloxacin—SLC22A6—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC11A1—multiple sclerosis	0.000173	0.00858	CbGpPWpGaD
Norfloxacin—Asthenia—Triamcinolone—multiple sclerosis	0.000172	0.000754	CcSEcCtD
Norfloxacin—Abdominal pain—Dexamethasone—multiple sclerosis	0.000172	0.000754	CcSEcCtD
Norfloxacin—Body temperature increased—Betamethasone—multiple sclerosis	0.000172	0.000754	CcSEcCtD
Norfloxacin—Body temperature increased—Dexamethasone—multiple sclerosis	0.000172	0.000754	CcSEcCtD
Norfloxacin—Abdominal pain—Betamethasone—multiple sclerosis	0.000172	0.000754	CcSEcCtD
Norfloxacin—Asthenia—Methylprednisolone—multiple sclerosis	0.000172	0.000753	CcSEcCtD
Norfloxacin—Insomnia—Prednisone—multiple sclerosis	0.000172	0.000751	CcSEcCtD
Norfloxacin—Paraesthesia—Prednisone—multiple sclerosis	0.000171	0.000746	CcSEcCtD
Norfloxacin—Pruritus—Triamcinolone—multiple sclerosis	0.00017	0.000744	CcSEcCtD
Norfloxacin—Pruritus—Methylprednisolone—multiple sclerosis	0.00017	0.000742	CcSEcCtD
Norfloxacin—Convulsion—Methotrexate—multiple sclerosis	0.000169	0.000737	CcSEcCtD
Norfloxacin—Dyspepsia—Prednisone—multiple sclerosis	0.000167	0.000731	CcSEcCtD
Norfloxacin—Chest pain—Methotrexate—multiple sclerosis	0.000166	0.000724	CcSEcCtD
Norfloxacin—Myalgia—Methotrexate—multiple sclerosis	0.000166	0.000724	CcSEcCtD
Norfloxacin—Arthralgia—Methotrexate—multiple sclerosis	0.000166	0.000724	CcSEcCtD
Norfloxacin—Decreased appetite—Prednisone—multiple sclerosis	0.000165	0.000722	CcSEcCtD
Norfloxacin—Rash—Prednisolone—multiple sclerosis	0.000165	0.000721	CcSEcCtD
Norfloxacin—Dermatitis—Prednisolone—multiple sclerosis	0.000165	0.00072	CcSEcCtD
Norfloxacin—Diarrhoea—Methylprednisolone—multiple sclerosis	0.000164	0.000718	CcSEcCtD
Norfloxacin—Fatigue—Prednisone—multiple sclerosis	0.000164	0.000716	CcSEcCtD
Norfloxacin—Headache—Prednisolone—multiple sclerosis	0.000164	0.000716	CcSEcCtD
Norfloxacin—Constipation—Prednisone—multiple sclerosis	0.000162	0.00071	CcSEcCtD
Norfloxacin—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP27B1—multiple sclerosis	0.000162	0.00804	CbGpPWpGaD
Norfloxacin—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP24A1—multiple sclerosis	0.000162	0.00804	CbGpPWpGaD
Norfloxacin—CYP3A7—Biological oxidations—CYP24A1—multiple sclerosis	0.00016	0.00795	CbGpPWpGaD
Norfloxacin—CYP3A7—Biological oxidations—CYP27B1—multiple sclerosis	0.00016	0.00795	CbGpPWpGaD
Norfloxacin—Confusional state—Methotrexate—multiple sclerosis	0.00016	0.0007	CcSEcCtD
Norfloxacin—CYP1A2—Oxidation by Cytochrome P450—CYP24A1—multiple sclerosis	0.00016	0.00794	CbGpPWpGaD
Norfloxacin—CYP1A2—Oxidation by Cytochrome P450—CYP27B1—multiple sclerosis	0.00016	0.00794	CbGpPWpGaD
Norfloxacin—Dizziness—Triamcinolone—multiple sclerosis	0.000159	0.000695	CcSEcCtD
Norfloxacin—Anaphylactic shock—Methotrexate—multiple sclerosis	0.000159	0.000694	CcSEcCtD
Norfloxacin—Dizziness—Methylprednisolone—multiple sclerosis	0.000159	0.000694	CcSEcCtD
Norfloxacin—CYP3A7—Metapathway biotransformation—CYP24A1—multiple sclerosis	0.000158	0.00784	CbGpPWpGaD
Norfloxacin—CYP3A7—Metapathway biotransformation—CYP27B1—multiple sclerosis	0.000158	0.00784	CbGpPWpGaD
Norfloxacin—Feeling abnormal—Prednisone—multiple sclerosis	0.000157	0.000685	CcSEcCtD
Norfloxacin—Asthenia—Dexamethasone—multiple sclerosis	0.000156	0.000684	CcSEcCtD
Norfloxacin—Asthenia—Betamethasone—multiple sclerosis	0.000156	0.000684	CcSEcCtD
Norfloxacin—Thrombocytopenia—Methotrexate—multiple sclerosis	0.000155	0.00068	CcSEcCtD
Norfloxacin—Gastrointestinal pain—Prednisone—multiple sclerosis	0.000155	0.000679	CcSEcCtD
Norfloxacin—Nausea—Prednisolone—multiple sclerosis	0.000155	0.000679	CcSEcCtD
Norfloxacin—Pruritus—Betamethasone—multiple sclerosis	0.000154	0.000675	CcSEcCtD
Norfloxacin—Pruritus—Dexamethasone—multiple sclerosis	0.000154	0.000675	CcSEcCtD
Norfloxacin—Hyperhidrosis—Methotrexate—multiple sclerosis	0.000153	0.000671	CcSEcCtD
Norfloxacin—Vomiting—Triamcinolone—multiple sclerosis	0.000153	0.000669	CcSEcCtD
Norfloxacin—Vomiting—Methylprednisolone—multiple sclerosis	0.000152	0.000667	CcSEcCtD
Norfloxacin—Rash—Triamcinolone—multiple sclerosis	0.000152	0.000663	CcSEcCtD
Norfloxacin—Dermatitis—Triamcinolone—multiple sclerosis	0.000151	0.000662	CcSEcCtD
Norfloxacin—Anorexia—Methotrexate—multiple sclerosis	0.000151	0.000662	CcSEcCtD
Norfloxacin—Rash—Methylprednisolone—multiple sclerosis	0.000151	0.000661	CcSEcCtD
Norfloxacin—Dermatitis—Methylprednisolone—multiple sclerosis	0.000151	0.000661	CcSEcCtD
Norfloxacin—Urticaria—Prednisone—multiple sclerosis	0.000151	0.00066	CcSEcCtD
Norfloxacin—Headache—Triamcinolone—multiple sclerosis	0.000151	0.000659	CcSEcCtD
Norfloxacin—Headache—Methylprednisolone—multiple sclerosis	0.00015	0.000657	CcSEcCtD
Norfloxacin—Abdominal pain—Prednisone—multiple sclerosis	0.00015	0.000657	CcSEcCtD
Norfloxacin—Body temperature increased—Prednisone—multiple sclerosis	0.00015	0.000657	CcSEcCtD
Norfloxacin—Diarrhoea—Betamethasone—multiple sclerosis	0.000149	0.000653	CcSEcCtD
Norfloxacin—Diarrhoea—Dexamethasone—multiple sclerosis	0.000149	0.000653	CcSEcCtD
Norfloxacin—SLC22A5—SLC-mediated transmembrane transport—SLC30A7—multiple sclerosis	0.000149	0.00739	CbGpPWpGaD
Norfloxacin—SLC22A6—SLC-mediated transmembrane transport—SLC15A2—multiple sclerosis	0.000148	0.00736	CbGpPWpGaD
Norfloxacin—CYP2A6—Biological oxidations—CYP27B1—multiple sclerosis	0.000147	0.00729	CbGpPWpGaD
Norfloxacin—CYP2A6—Biological oxidations—CYP24A1—multiple sclerosis	0.000147	0.00729	CbGpPWpGaD
Norfloxacin—Musculoskeletal discomfort—Methotrexate—multiple sclerosis	0.000145	0.000633	CcSEcCtD
Norfloxacin—Dizziness—Betamethasone—multiple sclerosis	0.000144	0.000631	CcSEcCtD
Norfloxacin—Dizziness—Dexamethasone—multiple sclerosis	0.000144	0.000631	CcSEcCtD
Norfloxacin—Insomnia—Methotrexate—multiple sclerosis	0.000144	0.000628	CcSEcCtD
Norfloxacin—Nausea—Triamcinolone—multiple sclerosis	0.000143	0.000625	CcSEcCtD
Norfloxacin—Paraesthesia—Methotrexate—multiple sclerosis	0.000143	0.000623	CcSEcCtD
Norfloxacin—Nausea—Methylprednisolone—multiple sclerosis	0.000142	0.000623	CcSEcCtD
Norfloxacin—Dyspnoea—Methotrexate—multiple sclerosis	0.000142	0.000619	CcSEcCtD
Norfloxacin—Somnolence—Methotrexate—multiple sclerosis	0.000141	0.000617	CcSEcCtD
Norfloxacin—Hypersensitivity—Prednisone—multiple sclerosis	0.00014	0.000612	CcSEcCtD
Norfloxacin—Dyspepsia—Methotrexate—multiple sclerosis	0.00014	0.000611	CcSEcCtD
Norfloxacin—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL12A—multiple sclerosis	0.000139	0.0069	CbGpPWpGaD
Norfloxacin—Vomiting—Dexamethasone—multiple sclerosis	0.000139	0.000607	CcSEcCtD
Norfloxacin—Vomiting—Betamethasone—multiple sclerosis	0.000139	0.000607	CcSEcCtD
Norfloxacin—Decreased appetite—Methotrexate—multiple sclerosis	0.000138	0.000604	CcSEcCtD
Norfloxacin—Rash—Betamethasone—multiple sclerosis	0.000138	0.000602	CcSEcCtD
Norfloxacin—Rash—Dexamethasone—multiple sclerosis	0.000138	0.000602	CcSEcCtD
Norfloxacin—Dermatitis—Betamethasone—multiple sclerosis	0.000137	0.000601	CcSEcCtD
Norfloxacin—Dermatitis—Dexamethasone—multiple sclerosis	0.000137	0.000601	CcSEcCtD
Norfloxacin—Fatigue—Methotrexate—multiple sclerosis	0.000137	0.000599	CcSEcCtD
Norfloxacin—CYP1A1—Aryl Hydrocarbon Receptor Pathway—IL12B—multiple sclerosis	0.000137	0.00679	CbGpPWpGaD
Norfloxacin—Headache—Dexamethasone—multiple sclerosis	0.000137	0.000598	CcSEcCtD
Norfloxacin—Headache—Betamethasone—multiple sclerosis	0.000137	0.000598	CcSEcCtD
Norfloxacin—Asthenia—Prednisone—multiple sclerosis	0.000136	0.000596	CcSEcCtD
Norfloxacin—TOP2A—Gastric Cancer Network 2—MYC—multiple sclerosis	0.000136	0.00675	CbGpPWpGaD
Norfloxacin—Pruritus—Prednisone—multiple sclerosis	0.000134	0.000588	CcSEcCtD
Norfloxacin—CYP1A2—Phase 1 - Functionalization of compounds—CYP24A1—multiple sclerosis	0.000131	0.00652	CbGpPWpGaD
Norfloxacin—CYP1A2—Phase 1 - Functionalization of compounds—CYP27B1—multiple sclerosis	0.000131	0.00652	CbGpPWpGaD
Norfloxacin—Feeling abnormal—Methotrexate—multiple sclerosis	0.000131	0.000572	CcSEcCtD
Norfloxacin—Diarrhoea—Prednisone—multiple sclerosis	0.00013	0.000568	CcSEcCtD
Norfloxacin—Gastrointestinal pain—Methotrexate—multiple sclerosis	0.00013	0.000568	CcSEcCtD
Norfloxacin—Nausea—Dexamethasone—multiple sclerosis	0.00013	0.000567	CcSEcCtD
Norfloxacin—Nausea—Betamethasone—multiple sclerosis	0.00013	0.000567	CcSEcCtD
Norfloxacin—Urticaria—Methotrexate—multiple sclerosis	0.000126	0.000552	CcSEcCtD
Norfloxacin—Dizziness—Prednisone—multiple sclerosis	0.000126	0.000549	CcSEcCtD
Norfloxacin—Body temperature increased—Methotrexate—multiple sclerosis	0.000125	0.000549	CcSEcCtD
Norfloxacin—Abdominal pain—Methotrexate—multiple sclerosis	0.000125	0.000549	CcSEcCtD
Norfloxacin—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP24A1—multiple sclerosis	0.000125	0.00621	CbGpPWpGaD
Norfloxacin—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP27B1—multiple sclerosis	0.000125	0.00621	CbGpPWpGaD
Norfloxacin—CYP3A4—Oxidation by Cytochrome P450—CYP24A1—multiple sclerosis	0.000123	0.00613	CbGpPWpGaD
Norfloxacin—CYP3A4—Oxidation by Cytochrome P450—CYP27B1—multiple sclerosis	0.000123	0.00613	CbGpPWpGaD
Norfloxacin—Vomiting—Prednisone—multiple sclerosis	0.000121	0.000528	CcSEcCtD
Norfloxacin—CYP1A1—Estrogen Receptor Pathway—STAT3—multiple sclerosis	0.000121	0.006	CbGpPWpGaD
Norfloxacin—Rash—Prednisone—multiple sclerosis	0.00012	0.000524	CcSEcCtD
Norfloxacin—Dermatitis—Prednisone—multiple sclerosis	0.00012	0.000523	CcSEcCtD
Norfloxacin—Headache—Prednisone—multiple sclerosis	0.000119	0.00052	CcSEcCtD
Norfloxacin—CYP1A1—Melatonin metabolism and effects—APOE—multiple sclerosis	0.000119	0.00591	CbGpPWpGaD
Norfloxacin—Hypersensitivity—Methotrexate—multiple sclerosis	0.000117	0.000512	CcSEcCtD
Norfloxacin—CYP3A5—Biological oxidations—CYP27B1—multiple sclerosis	0.000116	0.00575	CbGpPWpGaD
Norfloxacin—CYP3A5—Biological oxidations—CYP24A1—multiple sclerosis	0.000116	0.00575	CbGpPWpGaD
Norfloxacin—CYP3A5—Metapathway biotransformation—CYP24A1—multiple sclerosis	0.000114	0.00567	CbGpPWpGaD
Norfloxacin—CYP3A5—Metapathway biotransformation—CYP27B1—multiple sclerosis	0.000114	0.00567	CbGpPWpGaD
Norfloxacin—Asthenia—Methotrexate—multiple sclerosis	0.000114	0.000498	CcSEcCtD
Norfloxacin—Nausea—Prednisone—multiple sclerosis	0.000113	0.000493	CcSEcCtD
Norfloxacin—Pruritus—Methotrexate—multiple sclerosis	0.000112	0.000491	CcSEcCtD
Norfloxacin—SLC22A6—SLC-mediated transmembrane transport—SLC30A7—multiple sclerosis	0.000112	0.00558	CbGpPWpGaD
Norfloxacin—CYP3A4—Drug Induction of Bile Acid Pathway—VDR—multiple sclerosis	0.000112	0.00557	CbGpPWpGaD
Norfloxacin—CYP1A1—Biological oxidations—CYP27B1—multiple sclerosis	0.000109	0.00543	CbGpPWpGaD
Norfloxacin—CYP1A1—Biological oxidations—CYP24A1—multiple sclerosis	0.000109	0.00543	CbGpPWpGaD
Norfloxacin—Diarrhoea—Methotrexate—multiple sclerosis	0.000109	0.000475	CcSEcCtD
Norfloxacin—CYP1A1—Metapathway biotransformation—CYP24A1—multiple sclerosis	0.000108	0.00536	CbGpPWpGaD
Norfloxacin—CYP1A1—Metapathway biotransformation—CYP27B1—multiple sclerosis	0.000108	0.00536	CbGpPWpGaD
Norfloxacin—Dizziness—Methotrexate—multiple sclerosis	0.000105	0.000459	CcSEcCtD
Norfloxacin—SLC22A5—SLC-mediated transmembrane transport—SLC11A1—multiple sclerosis	0.000104	0.00517	CbGpPWpGaD
Norfloxacin—CYP3A4—Phase 1 - Functionalization of compounds—CYP27B1—multiple sclerosis	0.000101	0.00503	CbGpPWpGaD
Norfloxacin—CYP3A4—Phase 1 - Functionalization of compounds—CYP24A1—multiple sclerosis	0.000101	0.00503	CbGpPWpGaD
Norfloxacin—TOP2A—Integrated Pancreatic Cancer Pathway—TNFRSF1A—multiple sclerosis	0.000101	0.00503	CbGpPWpGaD
Norfloxacin—Vomiting—Methotrexate—multiple sclerosis	0.000101	0.000441	CcSEcCtD
Norfloxacin—Rash—Methotrexate—multiple sclerosis	0.0001	0.000438	CcSEcCtD
Norfloxacin—Dermatitis—Methotrexate—multiple sclerosis	0.0001	0.000437	CcSEcCtD
Norfloxacin—SLC22A5—Transmembrane transport of small molecules—SLC15A2—multiple sclerosis	9.98e-05	0.00496	CbGpPWpGaD
Norfloxacin—Headache—Methotrexate—multiple sclerosis	9.94e-05	0.000435	CcSEcCtD
Norfloxacin—Nausea—Methotrexate—multiple sclerosis	9.43e-05	0.000412	CcSEcCtD
Norfloxacin—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL12B—multiple sclerosis	8.72e-05	0.00433	CbGpPWpGaD
Norfloxacin—CYP3A7—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	8.36e-05	0.00416	CbGpPWpGaD
Norfloxacin—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—multiple sclerosis	8.34e-05	0.00415	CbGpPWpGaD
Norfloxacin—TOP2A—Integrated Pancreatic Cancer Pathway—BDNF—multiple sclerosis	8.13e-05	0.00404	CbGpPWpGaD
Norfloxacin—SLC22A6—SLC-mediated transmembrane transport—SLC11A1—multiple sclerosis	7.85e-05	0.0039	CbGpPWpGaD
Norfloxacin—CYP1A2—Estrogen Receptor Pathway—STAT3—multiple sclerosis	7.7e-05	0.00383	CbGpPWpGaD
Norfloxacin—CYP2A6—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	7.67e-05	0.00381	CbGpPWpGaD
Norfloxacin—CYP1A2—Melatonin metabolism and effects—APOE—multiple sclerosis	7.58e-05	0.00377	CbGpPWpGaD
Norfloxacin—SLC22A5—Transmembrane transport of small molecules—SLC30A7—multiple sclerosis	7.56e-05	0.00376	CbGpPWpGaD
Norfloxacin—SLC22A6—Transmembrane transport of small molecules—SLC15A2—multiple sclerosis	7.53e-05	0.00374	CbGpPWpGaD
Norfloxacin—CYP1A2—Biological oxidations—CYP24A1—multiple sclerosis	6.97e-05	0.00346	CbGpPWpGaD
Norfloxacin—CYP1A2—Biological oxidations—CYP27B1—multiple sclerosis	6.97e-05	0.00346	CbGpPWpGaD
Norfloxacin—TOP2A—Integrated Pancreatic Cancer Pathway—FAS—multiple sclerosis	6.96e-05	0.00346	CbGpPWpGaD
Norfloxacin—CYP1A2—Metapathway biotransformation—CYP27B1—multiple sclerosis	6.88e-05	0.00342	CbGpPWpGaD
Norfloxacin—CYP1A2—Metapathway biotransformation—CYP24A1—multiple sclerosis	6.88e-05	0.00342	CbGpPWpGaD
Norfloxacin—CYP3A7—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	6.78e-05	0.00337	CbGpPWpGaD
Norfloxacin—TOP2A—Circadian rythm related genes—FAS—multiple sclerosis	6.68e-05	0.00332	CbGpPWpGaD
Norfloxacin—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—multiple sclerosis	6.44e-05	0.0032	CbGpPWpGaD
Norfloxacin—CYP2A6—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	6.21e-05	0.00309	CbGpPWpGaD
Norfloxacin—CYP3A5—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	6.05e-05	0.003	CbGpPWpGaD
Norfloxacin—SLC22A5—Transmembrane transport of small molecules—AQP4—multiple sclerosis	5.98e-05	0.00297	CbGpPWpGaD
Norfloxacin—TOP2A—Retinoblastoma (RB) in Cancer—MYC—multiple sclerosis	5.95e-05	0.00296	CbGpPWpGaD
Norfloxacin—CYP1A1—Aryl Hydrocarbon Receptor Pathway—IFNG—multiple sclerosis	5.88e-05	0.00292	CbGpPWpGaD
Norfloxacin—CYP1A1—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	5.71e-05	0.00284	CbGpPWpGaD
Norfloxacin—SLC22A6—Transmembrane transport of small molecules—SLC30A7—multiple sclerosis	5.71e-05	0.00284	CbGpPWpGaD
Norfloxacin—CYP3A4—Biological oxidations—CYP27B1—multiple sclerosis	5.38e-05	0.00267	CbGpPWpGaD
Norfloxacin—CYP3A4—Biological oxidations—CYP24A1—multiple sclerosis	5.38e-05	0.00267	CbGpPWpGaD
Norfloxacin—CYP3A4—Metapathway biotransformation—CYP24A1—multiple sclerosis	5.31e-05	0.00264	CbGpPWpGaD
Norfloxacin—CYP3A4—Metapathway biotransformation—CYP27B1—multiple sclerosis	5.31e-05	0.00264	CbGpPWpGaD
Norfloxacin—SLC22A5—Transmembrane transport of small molecules—SLC11A1—multiple sclerosis	5.28e-05	0.00263	CbGpPWpGaD
Norfloxacin—CYP1A1—Aryl Hydrocarbon Receptor Pathway—IL1B—multiple sclerosis	5.24e-05	0.0026	CbGpPWpGaD
Norfloxacin—CYP1A1—Aryl Hydrocarbon Receptor Pathway—IL2—multiple sclerosis	5.22e-05	0.00259	CbGpPWpGaD
Norfloxacin—CYP3A5—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	4.9e-05	0.00243	CbGpPWpGaD
Norfloxacin—CYP1A1—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	4.63e-05	0.0023	CbGpPWpGaD
Norfloxacin—SLC22A6—Transmembrane transport of small molecules—AQP4—multiple sclerosis	4.51e-05	0.00224	CbGpPWpGaD
Norfloxacin—CYP1A1—Metabolism of lipids and lipoproteins—CYP27B1—multiple sclerosis	4.2e-05	0.00209	CbGpPWpGaD
Norfloxacin—CYP1A1—Metabolism of lipids and lipoproteins—CYP24A1—multiple sclerosis	4.2e-05	0.00209	CbGpPWpGaD
Norfloxacin—TOP2A—Mitotic G1-G1/S phases—MYC—multiple sclerosis	4.19e-05	0.00208	CbGpPWpGaD
Norfloxacin—CYP1A1—Aryl Hydrocarbon Receptor—MYC—multiple sclerosis	4.08e-05	0.00203	CbGpPWpGaD
Norfloxacin—CYP1A1—Aryl Hydrocarbon Receptor Pathway—TGFB1—multiple sclerosis	4.07e-05	0.00202	CbGpPWpGaD
Norfloxacin—CYP1A1—Aryl Hydrocarbon Receptor—MAPK1—multiple sclerosis	3.99e-05	0.00198	CbGpPWpGaD
Norfloxacin—SLC22A6—Transmembrane transport of small molecules—SLC11A1—multiple sclerosis	3.99e-05	0.00198	CbGpPWpGaD
Norfloxacin—CYP3A7—Metabolism—SRM—multiple sclerosis	3.89e-05	0.00193	CbGpPWpGaD
Norfloxacin—CYP1A1—Aryl Hydrocarbon Receptor Pathway—TNF—multiple sclerosis	3.8e-05	0.00189	CbGpPWpGaD
Norfloxacin—CYP1A1—Aryl Hydrocarbon Receptor—TNF—multiple sclerosis	3.8e-05	0.00189	CbGpPWpGaD
Norfloxacin—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IFNG—multiple sclerosis	3.75e-05	0.00186	CbGpPWpGaD
Norfloxacin—SLC22A5—SLC-mediated transmembrane transport—ALB—multiple sclerosis	3.74e-05	0.00186	CbGpPWpGaD
Norfloxacin—CYP1A2—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	3.64e-05	0.00181	CbGpPWpGaD
Norfloxacin—CYP3A7—Biological oxidations—POMC—multiple sclerosis	3.6e-05	0.00179	CbGpPWpGaD
Norfloxacin—CYP2A6—Metabolism—SRM—multiple sclerosis	3.56e-05	0.00177	CbGpPWpGaD
Norfloxacin—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL1B—multiple sclerosis	3.34e-05	0.00166	CbGpPWpGaD
Norfloxacin—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL2—multiple sclerosis	3.33e-05	0.00165	CbGpPWpGaD
Norfloxacin—CYP2A6—Biological oxidations—POMC—multiple sclerosis	3.3e-05	0.00164	CbGpPWpGaD
Norfloxacin—TOP2A—Integrated Pancreatic Cancer Pathway—MYC—multiple sclerosis	3.17e-05	0.00158	CbGpPWpGaD
Norfloxacin—TOP2A—Integrated Pancreatic Cancer Pathway—TGFB1—multiple sclerosis	3.16e-05	0.00157	CbGpPWpGaD
Norfloxacin—TOP2A—Integrated Pancreatic Cancer Pathway—MAPK1—multiple sclerosis	3.1e-05	0.00154	CbGpPWpGaD
Norfloxacin—TOP2A—Integrated Pancreatic Cancer Pathway—TNF—multiple sclerosis	2.95e-05	0.00147	CbGpPWpGaD
Norfloxacin—CYP1A2—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	2.95e-05	0.00147	CbGpPWpGaD
Norfloxacin—SLC22A6—SLC-mediated transmembrane transport—ALB—multiple sclerosis	2.83e-05	0.0014	CbGpPWpGaD
Norfloxacin—CYP3A4—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	2.81e-05	0.0014	CbGpPWpGaD
Norfloxacin—CYP3A5—Metabolism—SRM—multiple sclerosis	2.81e-05	0.0014	CbGpPWpGaD
Norfloxacin—CYP3A7—Metabolism—CYP27B1—multiple sclerosis	2.74e-05	0.00136	CbGpPWpGaD
Norfloxacin—CYP3A7—Metabolism—CYP24A1—multiple sclerosis	2.74e-05	0.00136	CbGpPWpGaD
Norfloxacin—CYP1A2—Metabolism of lipids and lipoproteins—CYP27B1—multiple sclerosis	2.68e-05	0.00133	CbGpPWpGaD
Norfloxacin—CYP1A2—Metabolism of lipids and lipoproteins—CYP24A1—multiple sclerosis	2.68e-05	0.00133	CbGpPWpGaD
Norfloxacin—CYP1A1—Metabolism—SRM—multiple sclerosis	2.65e-05	0.00132	CbGpPWpGaD
Norfloxacin—CYP1A2—Aryl Hydrocarbon Receptor—MYC—multiple sclerosis	2.6e-05	0.00129	CbGpPWpGaD
Norfloxacin—CYP3A5—Biological oxidations—POMC—multiple sclerosis	2.6e-05	0.00129	CbGpPWpGaD
Norfloxacin—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TGFB1—multiple sclerosis	2.6e-05	0.00129	CbGpPWpGaD
Norfloxacin—CYP1A2—Aryl Hydrocarbon Receptor—MAPK1—multiple sclerosis	2.55e-05	0.00127	CbGpPWpGaD
Norfloxacin—CYP2A6—Metabolism—CYP27B1—multiple sclerosis	2.51e-05	0.00125	CbGpPWpGaD
Norfloxacin—CYP2A6—Metabolism—CYP24A1—multiple sclerosis	2.51e-05	0.00125	CbGpPWpGaD
Norfloxacin—CYP3A7—Metabolism—GPC5—multiple sclerosis	2.5e-05	0.00124	CbGpPWpGaD
Norfloxacin—CYP1A1—Biological oxidations—POMC—multiple sclerosis	2.46e-05	0.00122	CbGpPWpGaD
Norfloxacin—CYP1A2—Aryl Hydrocarbon Receptor—TNF—multiple sclerosis	2.43e-05	0.00121	CbGpPWpGaD
Norfloxacin—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—multiple sclerosis	2.43e-05	0.00121	CbGpPWpGaD
Norfloxacin—CYP2A6—Metabolism—GPC5—multiple sclerosis	2.3e-05	0.00114	CbGpPWpGaD
Norfloxacin—TOP2A—Circadian rythm related genes—IL6—multiple sclerosis	2.29e-05	0.00114	CbGpPWpGaD
Norfloxacin—CYP3A4—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	2.28e-05	0.00113	CbGpPWpGaD
Norfloxacin—CYP2A6—NRF2 pathway—TGFB1—multiple sclerosis	2.17e-05	0.00108	CbGpPWpGaD
Norfloxacin—CYP3A7—Metabolism—RRM1—multiple sclerosis	2.07e-05	0.00103	CbGpPWpGaD
Norfloxacin—CYP3A5—Metabolism—CYP24A1—multiple sclerosis	1.98e-05	0.000983	CbGpPWpGaD
Norfloxacin—CYP3A5—Metabolism—CYP27B1—multiple sclerosis	1.98e-05	0.000983	CbGpPWpGaD
Norfloxacin—SLC22A5—Transmembrane transport of small molecules—ALB—multiple sclerosis	1.9e-05	0.000945	CbGpPWpGaD
Norfloxacin—CYP2A6—Metabolism—RRM1—multiple sclerosis	1.9e-05	0.000945	CbGpPWpGaD
Norfloxacin—CYP1A1—Metabolism—CYP24A1—multiple sclerosis	1.87e-05	0.000929	CbGpPWpGaD
Norfloxacin—CYP1A1—Metabolism—CYP27B1—multiple sclerosis	1.87e-05	0.000929	CbGpPWpGaD
Norfloxacin—CYP1A1—Metabolism of lipids and lipoproteins—BCHE—multiple sclerosis	1.83e-05	0.000908	CbGpPWpGaD
Norfloxacin—CYP3A5—Metabolism—GPC5—multiple sclerosis	1.81e-05	0.000899	CbGpPWpGaD
Norfloxacin—CYP1A1—Metabolism—GPC5—multiple sclerosis	1.71e-05	0.00085	CbGpPWpGaD
Norfloxacin—CYP1A2—Metabolism—SRM—multiple sclerosis	1.69e-05	0.000841	CbGpPWpGaD
Norfloxacin—CYP1A2—Biological oxidations—POMC—multiple sclerosis	1.57e-05	0.000779	CbGpPWpGaD
Norfloxacin—TOP2A—Cell Cycle, Mitotic—MYC—multiple sclerosis	1.54e-05	0.000763	CbGpPWpGaD
Norfloxacin—TOP2A—Cell Cycle, Mitotic—MAPK1—multiple sclerosis	1.5e-05	0.000746	CbGpPWpGaD
Norfloxacin—CYP3A5—Metabolism—RRM1—multiple sclerosis	1.5e-05	0.000745	CbGpPWpGaD
Norfloxacin—SLC22A6—Transmembrane transport of small molecules—ALB—multiple sclerosis	1.44e-05	0.000713	CbGpPWpGaD
Norfloxacin—CYP1A1—Metabolism—RRM1—multiple sclerosis	1.42e-05	0.000704	CbGpPWpGaD
Norfloxacin—TOP2A—Cell Cycle—MYC—multiple sclerosis	1.37e-05	0.000682	CbGpPWpGaD
Norfloxacin—TOP2A—Cell Cycle—MAPK1—multiple sclerosis	1.34e-05	0.000667	CbGpPWpGaD
Norfloxacin—CYP3A4—Metabolism—SRM—multiple sclerosis	1.31e-05	0.000649	CbGpPWpGaD
Norfloxacin—CYP3A4—Biological oxidations—POMC—multiple sclerosis	1.21e-05	0.000601	CbGpPWpGaD
Norfloxacin—CYP1A2—Metabolism—CYP27B1—multiple sclerosis	1.19e-05	0.000592	CbGpPWpGaD
Norfloxacin—CYP1A2—Metabolism—CYP24A1—multiple sclerosis	1.19e-05	0.000592	CbGpPWpGaD
Norfloxacin—CYP3A7—Metabolism—BCHE—multiple sclerosis	1.19e-05	0.000592	CbGpPWpGaD
Norfloxacin—CYP1A2—Metabolism of lipids and lipoproteins—BCHE—multiple sclerosis	1.17e-05	0.000579	CbGpPWpGaD
Norfloxacin—CYP1A1—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	1.1e-05	0.000546	CbGpPWpGaD
Norfloxacin—CYP2A6—Metabolism—BCHE—multiple sclerosis	1.09e-05	0.000543	CbGpPWpGaD
Norfloxacin—CYP1A2—Metabolism—GPC5—multiple sclerosis	1.09e-05	0.000542	CbGpPWpGaD
Norfloxacin—CYP1A1—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	9.44e-06	0.000469	CbGpPWpGaD
Norfloxacin—CYP3A4—Metabolism—CYP24A1—multiple sclerosis	9.2e-06	0.000457	CbGpPWpGaD
Norfloxacin—CYP3A4—Metabolism—CYP27B1—multiple sclerosis	9.2e-06	0.000457	CbGpPWpGaD
Norfloxacin—CYP1A2—Metabolism—RRM1—multiple sclerosis	9.03e-06	0.000449	CbGpPWpGaD
Norfloxacin—CYP3A5—Metabolism—BCHE—multiple sclerosis	8.61e-06	0.000428	CbGpPWpGaD
Norfloxacin—CYP1A1—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	8.61e-06	0.000428	CbGpPWpGaD
Norfloxacin—CYP3A4—Metabolism—GPC5—multiple sclerosis	8.41e-06	0.000418	CbGpPWpGaD
Norfloxacin—CYP1A1—Metabolism—BCHE—multiple sclerosis	8.14e-06	0.000404	CbGpPWpGaD
Norfloxacin—CYP3A7—Metabolism—APOE—multiple sclerosis	7.17e-06	0.000356	CbGpPWpGaD
Norfloxacin—CYP1A2—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	7.01e-06	0.000348	CbGpPWpGaD
Norfloxacin—CYP3A4—Metabolism—RRM1—multiple sclerosis	6.97e-06	0.000346	CbGpPWpGaD
Norfloxacin—CYP2A6—Metabolism—APOE—multiple sclerosis	6.57e-06	0.000326	CbGpPWpGaD
Norfloxacin—CYP3A7—Metabolism—POMC—multiple sclerosis	6.16e-06	0.000306	CbGpPWpGaD
Norfloxacin—CYP1A2—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	6.02e-06	0.000299	CbGpPWpGaD
Norfloxacin—CYP2A6—Metabolism—POMC—multiple sclerosis	5.64e-06	0.00028	CbGpPWpGaD
Norfloxacin—CYP3A7—Metabolism—ALB—multiple sclerosis	5.61e-06	0.000279	CbGpPWpGaD
Norfloxacin—CYP1A2—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	5.49e-06	0.000273	CbGpPWpGaD
Norfloxacin—CYP1A2—Metabolism—BCHE—multiple sclerosis	5.19e-06	0.000258	CbGpPWpGaD
Norfloxacin—CYP3A5—Metabolism—APOE—multiple sclerosis	5.18e-06	0.000257	CbGpPWpGaD
Norfloxacin—CYP2A6—Metabolism—ALB—multiple sclerosis	5.15e-06	0.000256	CbGpPWpGaD
Norfloxacin—CYP1A1—Metabolism—APOE—multiple sclerosis	4.9e-06	0.000243	CbGpPWpGaD
Norfloxacin—CYP3A5—Metabolism—POMC—multiple sclerosis	4.45e-06	0.000221	CbGpPWpGaD
Norfloxacin—CYP1A1—Metabolism—POMC—multiple sclerosis	4.21e-06	0.000209	CbGpPWpGaD
Norfloxacin—CYP3A5—Metabolism—ALB—multiple sclerosis	4.06e-06	0.000202	CbGpPWpGaD
Norfloxacin—CYP3A4—Metabolism—BCHE—multiple sclerosis	4e-06	0.000199	CbGpPWpGaD
Norfloxacin—CYP1A1—Metabolism—ALB—multiple sclerosis	3.83e-06	0.000191	CbGpPWpGaD
Norfloxacin—CYP1A2—Metabolism—APOE—multiple sclerosis	3.12e-06	0.000155	CbGpPWpGaD
Norfloxacin—CYP1A2—Metabolism—POMC—multiple sclerosis	2.68e-06	0.000133	CbGpPWpGaD
Norfloxacin—CYP1A2—Metabolism—ALB—multiple sclerosis	2.44e-06	0.000121	CbGpPWpGaD
Norfloxacin—CYP3A4—Metabolism—APOE—multiple sclerosis	2.41e-06	0.00012	CbGpPWpGaD
Norfloxacin—CYP3A4—Metabolism—POMC—multiple sclerosis	2.07e-06	0.000103	CbGpPWpGaD
Norfloxacin—CYP3A4—Metabolism—ALB—multiple sclerosis	1.89e-06	9.38e-05	CbGpPWpGaD
